Grover’s disease associated with Sarcoptes scabiei: case report

Doença de Grover associada a Sarcoptes Scabiei: relato de caso

José Henrique Pereira Pinto1, Chan I Lym2, Clarissa Maria Serpa Vieira3, Chan Kun Wa4, Chan I Thien4

DOI: 10.5935/2238-3182.20140063

INTRODUCTION

The Grover’s disease (GD) was described by the American dermatologist Ralph Grover in 1970. In his account, he described the cases of six patients who presented papular and papulovesicular lesions located on the trunk and accompanied by intense itching, which appeared in the changing seasons and regressed after a few weeks. The biopsy of these lesions showed small foci motivating the author to name the disease as transient acantholytic dermatosis (TAD).

The first TAD case described in Brazil was published by Azulay-Abulafia in 1986, and only two other cases were described later by Manfrinato et al.1 in 1999. Although GD is characterized by a self-limited transitional course2 with an average duration of 22 months, according to an article by Mark D.P. Davis et al.,3 some patients present chronic manifestations of the disease.1,4 In his analysis of 72 cases, 13 patients presented recurrences in varying periods.3
Most GD cases portray white men over 40 years old and the extension and duration of illness worsens with the patients' advanced age.1,7

CASE REPORT

Male patient, Eastern ethnicity, age 53 years old. In October 2007, came into contact with a patient with scabies (*Sarcoptes scabiei*). Acquired this parasitosis showing papulo-eritematosus lesions of approximately 3 mm, followed by intense itching around the trunk and proximal portions of upper and lower limbs. The patient was treated with 15 mg ivermectin (single dose) and 50 mg/mL permethrin topical lotion, with partial resolution of symptoms.

After two weeks, the dermatological framework worsened. The lesions merged and formed erythematous plaques with diameters ranging between 2 and 4 cms, across the trunk and proximal regions of upper and lower limbs (Figures 1 and 2). These lesions were accompanied by intense itching and painful sensation. Heat and sweat were reported as worsening factors; and bath with cold water as an improving aid.

On physical examination, the patient only presented skin lesions. The laboratory tests were normal. He used 20 mg/day prednisone and 75 mg/day hydroxyzine without improvement. The biopsy of skin lesions and histopathological findings are compatible with Grover's disease.

Treatment with methotrexate was started at the dose of 15 mg per week for 10 weeks; a rapid remission was observed. After six months, however, the recurrence of lesions occurred. We decided to restart the treatment with methotrexate, in the same dose, during 12 weeks, associated with retinol acetate (50,000 IU/day) and the suspension of aerobic physical activity; the lesions regressed promptly.

Currently, the patient continues with the daily use of retinol acetate (50,000 IU/day), showing skin lesions compatible with Grover disease on the trunk and in small numbers (Figure 3).
DISCUSSION

The Grover’s disease is characterized by papular, papulovesicular, or papular keratotic formations that can vary from 1 to 10 mm. Several vesiculopustular, bullous, follicular, herpetiformis, and erythematous forms have already been described. The most common locations of eruptions are the chest and root of members, while scalp, face, and neck are less affected. There have been rare descriptions in the literature of incidence in mucous membranes and palms and soles. In an exacerbation, the erythematous papules may converge, forming erythematous plaques (Figures 1 and 2). The itching is a frequent complaint, and its intensity is variable. When intense, it is accompanied by a burning feeling that is difficult to control. The age group most affected by GD includes individuals over the fifth decade in age, with predominance of the Caucasian ethnicity, and with a men to women ratio of 3:1, which according to some authors it can be up to 8:1.

Many factors have been associated with this disease and are presented as triggering and/or aggravating symptoms. Physical factors such as: heat, exposure to sunlight, ionizing radiation, excessive sweating, and fever are described with frequency. Others such as skin irritation and inflammation, skin infections caused by Malassezia furfur, Demodex folliculorum, and Sarcoptes scabiei, trauma, pregnancy, bed rest in prolonged hospitalizations, and polyester apparel have also been reported. To a lesser number of descriptions, are non-infectious skin diseases that would trigger GD found in literature such as: astematotic eczema, contact dermatitis, atopic dermatitis, bullous and follicular pemphigus, lichen planus, psoriasis, pyoderma gangrenosum, seborrheic dermatitis, and versicolor pityriasis.


In its original publication, Grover suggested that the GD would be a form of irritant dermatitis in people genetically predisposed. According to some authors, a dermatological reaction to a paraneoplastic syndrome would also be a possible explanation.

In regards to the present case, it is possible that an allergic reaction to the mite Sarcoptes scabiei or its products have exacerbated an immediate hypersensitivity reaction and late in the patient causing skin lesions and producing the symptoms.

The GD diagnosis is based on histopathological finding of focal acantholysis, with or without spongiosis, in the epidermis and supra-basal level or subcorneal in skin specimen submitted to biopsy. In some cases, it is histologically indistinguishable from other acantholytic diseases (for example, the Darier disease), and the clinical and histological correlation in all cases needs to be performed.

The GD is an under-diagnosed disease, probably due to the large number of oligosymptomatic cases and/or transient or due to the fact that the disease clinically co-exists or is confused with other illnesses making diagnosis difficult.

It was in 1977 that Chalet et al. described the four histological forms currently accepted and which are characterized by acantholysis with formation of vesicles: similar pattern to vulgaris or foliaceus pemphigus, Darier disease-like pattern, Hailey-Hailey disease-like pattern, and a pattern with focal spongiosis. The pemphigus vulgaris-like and Darier-simile patterns are the most common.

In the case of our patient, the biopsy and histopathological examination of two skin segments showed findings compatible with pemphigus foliaceus-like forms, Darier-like, and Hailey-Hailey-simile.

As for the GD treatment, there is no standardization of conduct. Measures to prevent excessive sweating should be introduced early such as avoiding exposure to the sun, heat, and intense physical activity. It is important, also, to minimize skin irritation by using mild soaps, light-colored cotton fabrics, and adequate hydration.

In mild manifestations, the use of topical substances has shown a reduction of lesions and improvement of pruritus. Normally, vitamin A derivatives, calcipotriol, lactic acid lotions, urea ointments, zinc oxide ointment, and corticosteroids are used for these purposes.

Systemic therapy is recommended in the most extensive and persistent lesions. The literature describes the use of retinoids (isotretinoin and etreti-
nate) and cytostatics (methotrexate) besides steroids (prednisone and triamcinolone) for the remission of lesions. It is observed that the recurrence of lesions is frequent at the end of treatment with corticosteroids. Some studies show that the use of phototherapy with psoralen and ultraviolet A (PUVA) may be a useful resource; however, its mechanism of action is not fully understood. In cases where the itching is very intense, antihistamines (hydroxyzine, cetirizine) can be used as adjunctive therapy. Antibiotics (tetracycline and erythromycin) and antifungals (itraconazole) are indicated when there is secondary infection.

REFERENCES